Bexion Pharmaceuticals

About:

Bexion Pharmaceuticals is a privately-held biotech company focused on the development and commercialization of innovative cures for cancer.

Website: http://www.bexionpharma.com

Twitter/X: bexionpharma

Top Investors: Michael J. Fox Foundation, Keyhorse Capital (KSTC)

Description:

Bexion Pharmaceuticals is developing innovative cures for cancer. Unlike any other potential drug known in development, BXQ-350 has an entirely new and novel mechanism of action. Studies strongly suggest that specific tumor targeting is the result of targeting Phosphatidylserine patches that are characteristic of tumor cells and neovasculature; and that apoptosis results from activation of acid sphingomyelinase, subsequent generation of ceramide, and elevated levels of caspase.

Total Funding Amount:

$18M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Covington, Kentucky, United States

Founded Date:

2006-01-01

Contact Email:

bd(AT)bexionpharma.com

Founders:

Cameron Durrant

Number of Employees:

11-50

Last Funding Date:

2024-11-14

IPO Status:

Private

Industries:

© 2025 bioDAO.ai